Please login to the form below

Not currently logged in
Email:
Password:

Galectin Therapuetics appoints Harold Shlevin as chief operating officer

Will replace company co-founder Maureen Foley

Harold ShlevinDr Harold Shlevin has been appointed chief operating officer of Galectin Therapeutics, a US-based company that develops therapeutics that target galectin proteins to treat fibrosis and cancer.

Dr Shlevin (pictured) will take over from company co-founder Maureen Foley on October 1, 2012, as Galectin looks to advance its drug candidates.

Peter Traber, president, CEO and chief marketing offcier of Galectin said: “Dr Shlevin will be a tremendous asset to Galectin Therapeutics as he brings a broad range of technical, managerial and leadership experience in small, medium and large pharmaceutical companies that includes a track-record of attracting capital, competing successfully to negotiate partnering deals and developing and commercialising new pharmaceutical products.”

Most recently, Dr Shlevin led Georgia Institute of Technology's Advanced Technology Development Center (ATDC) as principle and manager of bioscience commercialisation efforts, where he helped the development of new bioscience startup companes.

Previously, he served as president and CEO of Solvay Pharmaceuticals, where he oversaw the successful launch of the first topical testosterone gel product in the US and he was co-founder of CIBA Vision Ophthalmics, a specialty ophthalmic drug company.

He also founded, and was president and CEO of, Tikvah Therapeutics, a company focused on clinical development of therapeutics for treatment of neurological diseases, and was once also VP and head of operations and commercial development for Altea Therapeutics Corporation.

31st August 2012

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

Flu
Influenza – the risk to vulnerable populations
Why we can't get complacent about flu vaccination...
dementia
Alzheimer’s Research UK highlights socio-economic inequalities in dementia risk
The charity aims to improve the number of women participating in dementia research and grow awareness of dementia risk factors...
Data security
Concerns about data security are building a strong case for clinical mobility in EMEA
Electronic medical records have transformed the storage of sensitive information but how can the healthcare sector continue to protect patient and staff data?...